Neurocrine Biosciences | NBIX - Market Capitalization


Neurocrine Biosciences reported $12.78B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 391.49B 12.34B Feb/2026
Acadia Pharmaceuticals USD 3.6B 10M Sep/2025
Agios Pharmaceuticals USD 1.6B 16M Feb/2026
ALKERMES USD 5.65B 696M Feb/2026
Alnylam Pharmaceuticals USD 39.74B 12.8B Feb/2026
Amgen USD 201.45B 25.2B Feb/2026
Biogen USD 27.01B 1.19B Feb/2026
BioMarin Pharmaceutical USD 11.99B 575M Feb/2026
Cytokinetics USD 8.27B 504M Feb/2026
Enanta Pharmaceuticals USD 198M 37M Dec/2023
Exelixis USD 12.27B 523M Feb/2026
Gilead Sciences USD 183.59B 31.31B Feb/2026
Halozyme Therapeutics USD 10.23B 2.31B Feb/2026
Incyte USD 22.7B 3.31B Feb/2026
Ionis Pharmaceuticals USD 10.43B 4.14B Sep/2025
Nektar Therapeutics USD 113M 4M Sep/2023
Neurocrine Biosciences USD 13.68B 465M Feb/2026
Pfizer USD 152.89B 11.32B Feb/2026
Prothena USD 473M 52M Feb/2026
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Repligen USD 7.51B 1.71B Feb/2026
Rigel Pharmaceuticals USD 188M 36M Sep/2023
Sarepta Therapeutics USD 2.02B 336M Sep/2025
Teva Pharmaceutical Industries USD 36.42B 14.06B Dec/2025
Ultragenyx Pharmaceutical USD 1.94B 284M Feb/2026
Vertex Pharmaceuticals USD 120.12B 5.09B Feb/2026
Xoma USD 162M 55M Sep/2023